Race Oncology Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Melbourne Australia (1993)

Organization Overview

First Clinical Trial
2019
NCT03820908
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Race Oncology Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 6